Sinopharm reports 2.95 percent lower profit: what it means for Sinopharm stock

Sinopharm Group Co. reported a 2.95 percent year-over-year decline in net profit to RMB 5.18 billion for the six months ended June 30, 2026, according to FilingReader on September 22, 2026. The result puts distribution weakness alongside a growing retail business as the central issue for Sinopharm stock.

Profit declines in first half

Operating income reached RMB 282.8 billion in the first half of 2026, down 1.13 percent from the same period a year earlier. Net profit attributable to shareholders fell 1.79 percent to RMB 3.4 billion, while basic earnings per share declined 1.80 percent to RMB 1.09, the interim report said through FilingReader.

The pressure was concentrated in the core distribution activities. Pharmaceutical distribution revenue fell 1.39 percent to RMB 215.5 billion, while medical device distribution revenue decreased 0.35 percent to RMB 56.9 billion in the first half of 2026.

Retail growth softens the decline

Retail pharmacy revenue rose 8.58 percent to RMB 18.6 billion during the same period, creating a measurable counterweight to the distribution slowdown. The contrast matters because retail growth was positive while the group's largest business line contracted.

Futu reported that Sinopharm also recorded a 4.11 percent overall expense ratio for the first half of 2026, down 0.27 percentage points year over year. The company linked its strategy to tighter cost control, cash-flow security and continued development of pharmaceutical retail.

Governance adds a second signal

Sinopharm held an extraordinary general meeting on September 15, 2026. According to MarketScreener, the board elected Jin Bin as chairman and approved the structure of five board committees. The move preserves leadership continuity while the company manages weaker distribution revenue and expanding retail operations.

Assets remain substantial

Sinopharm reported total assets of RMB 404.4 billion and cash and cash equivalents of RMB 31.0 billion as of June 30, 2026, according to FilingReader. Those figures provide the balance-sheet context for the earnings decline and the group's focus on operating efficiency.